Facebook Linkedin RSS Twitter Youtube
Home 2024

10x Genomics

StockWatch: Phase III Data for Pfizer-Partnered Hemophilia A Gene Therapy Lifts Sangamo Shares
GEN Edge

StockWatch: Phase III Data for Pfizer-Partnered Hemophilia A Gene Therapy Lifts Sangamo Shares

StockWatch: As Illumina Expands in Multiomics, Analyst Sees Threat to 10x
GEN Edge

StockWatch: As Illumina Expands in Multiomics, Analyst Sees Threat to 10x

Aiming High: 10x, NanoString Launch Large-Scale Panels
GEN Edge

Aiming High: 10x, NanoString Launch Large-Scale Panels

New Kits Are Democratizing Single-Cell RNA Sequencing
Insights

New Kits Are Democratizing Single-Cell RNA Sequencing

Court Grants Vizgen Motion to Expand Antitrust Case vs.10x, Harvard
GEN Edge

Court Grants Vizgen Motion to Expand Antitrust Case vs.10x, Harvard

Bruker to Acquire NanoString with $392.6M Winning Bid
GEN Edge

Bruker to Acquire NanoString with $392.6M Winning Bid

As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?
GEN Edge

As 10x Launches Visium HD, Will Single Cell Resolution Draw New Customers?

10x Ships First Single Cell GEM-X Assays to Customers
GEN Edge

10x Ships First Single Cell GEM-X Assays to Customers

10x Defends Patent Litigation Strategy after Criticism from Researchers, Rivals
GEN Edge

10x Defends Patent Litigation Strategy after Criticism from Researchers, Rivals

The State of Omics 2024
Multimedia

The State of Omics 2024

123...7Page 1 of 7
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.